<?xml version="1.0" ?>
<tei>
	<teiHeader>
		<fileDesc xml:id="55012065"/>
	</teiHeader>
	<text xml:lang="en">
		<front>
<lb/>
	<note type="copyright">© 2009 Gaffo and Saag, publisher and licensee Dove Medical Press Ltd. This is an Open Access article<lb/> which permits unrestricted noncommercial use, provided the original work is properly cited.<lb/></note>

	<reference>Core Evidence 2009:4 25–36<lb/></reference>

	<note type="other">Core Evidence<lb/> </note>

	<note type="page">25<lb/> </note>

	<note type="other">r E v i E w<lb/>  Dovepress<lb/>  open access to scientific and medical research<lb/> Open Access Full Text Article<lb/> submit your manuscript | </note>

	<ptr>www.dovepress.com<lb/></ptr>

	<note type="other">Dovepress<lb/></note>

	<docTitle>
	<titlePart>Febuxostat: the evidence for its use<lb/> in the treatment of hyperuricemia and gout<lb/></titlePart>
	</docTitle>

	<byline>
	<docAuthor>Angelo L Gaffo<lb/> 1<lb/> Kenneth G Saag<lb/> 2<lb/></docAuthor>
	</byline>

	<byline>
	<affiliation>1 Birmingham vA Medical Center,<lb/> 2 Division of Clinical immunology<lb/> and rheumatology, University<lb/> of Alabama at Birmingham<lb/> </affiliation>
	</byline>
	
	<note type="other">Correspondence: </note>

	<byline>
	<docAuthor>Kenneth G Saag<lb/></docAuthor>
	</byline>

	<address>FOT 820, 1530 3rd Ave<lb/> S Birmingham, AL 35294, USA<lb/></address>

	<email>Email ksaag@uab.edu.<lb/></email>

		</front>
	</text>
</tei>
